Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Ambarella surges after report says company exploring strategic options, including sale (SeekingAlpha) +++ AMBARELLA Aktie +15,53%

PTC THERAPEUTICS Aktie

 >PTC THERA Aktienkurs 
43.6 EUR    +1.9%    (Tradegate)
Ask: 43 EUR / 80 Stück
Bid: 42.4 EUR / 80 Stück
Tagesumsatz: 55 Stück
Realtime Kurs von 8 bis 22 Uhr!
PTC THERA Aktie über LYNX handeln
>PTC THERA Performance
1 Woche: -1,4%
1 Monat: +7,9%
3 Monate: -17,7%
6 Monate: -0,5%
1 Jahr: +26,0%
laufendes Jahr: +0,5%
>PTC THERAPEUTICS Aktie
Name:  PTC THERAPEUTICS DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US69366J2006 / A1W0MW
Symbol/ Ticker:  BH3 (Frankfurt) / PTCT (NASDAQ)
Kürzel:  FRA:BH3, ETR:BH3, BH3:GR, NASDAQ:PTCT
Index:  -
Webseite:  https://www.ptcbio.com/
Marktkapitalisierung:  3520 Mio. EUR
Umsatz:  1532.24 Mio. EUR
EBITDA:  775.47 Mio. EUR
Gewinn je Aktie:  4.926 EUR
Schulden:  2155.53 Mio. EUR
Liquide Mittel:  1765.97 Mio. EUR
Umsatz-/ Gewinnwachstum:  459.7% / -
KGV/ KGV lG:  7.8 / 6.31
KUV/ KBV/ PEG:  2.27 / - / -
Gewinnm./ Eigenkapitalr.:  33.56% / -
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  PTC THERAPEUTICS, PTC THERAPEUTIC, PTC THERA
Letzte Datenerhebung:  24.06.25
>PTC THERA Eigentümer
Aktien: 79.26 Mio. St.
f.h. Aktien: 64.41 Mio. St.
Insider Eigner: 2.42%
Instit. Eigner: 101.06%
>PTC THERA Peer Group

 
24.06.25 - 20:03
 Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
 
– Broad label inclusive of all ages and disease severities – – Launch to be initiated in Germany – WARREN, N.J., June 24, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Sephience™ (sepiapterin) was granted marketing authorization by the European Commission......
24.06.25 - 09:45
 PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, June 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ: PTCT) for violations of the securities laws. The......
23.06.25 - 13:03
 Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
 
– Broad label inclusive of all ages and disease severities – – Launch to be initiated in Germany – WARREN, N.J., June 23, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Sephience™ (sepiapterin) was granted marketing authorization by the European Commission......
22.06.25 - 19:12
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT (PR Newswire)
 
NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
19.06.25 - 22:33
 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
WARREN, N.J., June 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,725 shares of its common stock and 27,790 restricted stock units ("RSUs"), each......
06.06.25 - 19:45
 All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy (Zacks)
 
PTC Therapeutics (PTCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....
05.06.25 - 23:33
 Friedreich′s Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight (PR Newswire)
 
The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe are thoroughly working toward the development of new drug therapy options to treat this disease. Key products such as RT001 (Retrotope), Vatiquinone (PTC Therapeutics), and Leriglitazone......
20.05.25 - 01:01
 Insiderhandel: EXEC. VP AND CLO verkauft Aktien von PTC Therapeutics im Wert von 89081 USD (Insiderkauf)
 
Boulding, Mark Elliott - Vorstand - Tag der Transaktion: 2025-05-15...
20.05.25 - 01:01
 Insiderhandel: EXEC. VP AND CLO verkauft Aktien von PTC Therapeutics im Wert von 40636 USD (Insiderkauf)
 
Boulding, Mark Elliott - Vorstand - Tag der Transaktion: 2025-05-16...
12.05.25 - 23:12
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT (PR Newswire)
 
NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
07.05.25 - 05:24
 PTC Therapeutics projects $650M to $800M revenue for 2025 amid global SUFIANCE launch preparations (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.05.25 - 00:54
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT (PR Newswire)
 
NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation......
07.05.25 - 00:36
 PTC Therapeutics (PTCT) Q1 2025 Earnings Call (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.25 - 22:03
 PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (PR Newswire)
 
– Strong revenue performance of $190 million – – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date – – Global Sephience launch activities progressing well – – Strong cash position of over $2.0 billion as of......
01.05.25 - 22:31
 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
WARREN, N.J., May 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that on April 25, 2025, the company approved non-statutory stock options to purchase an aggregate of 7,000 shares of its common stock and 10,780 restricted stock units ("RSUs"), each......
25.04.25 - 15:01
 PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
 
- Label includes full spectrum of PKU patients - - European launch preparations underway - WARREN, N.J., April 25, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency......
25.04.25 - 04:01
 Insiderhandel: CHIEF EXECUTIVE OFFICER verkauft Aktien von PTC Therapeutics im Wert von 136656 USD (Insiderkauf)
 
Klein, Matthew B. - Vorstand - Tag der Transaktion: 2025-04-22...
17.04.25 - 17:30
 PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy? (Zacks)
 
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
17.04.25 - 14:03
 PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results (PR Newswire)
 
WARREN, N.J., April 17, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, May 6, at 4:30......
05.04.25 - 02:01
 Insiderhandel: EVP & CHIEF MEDICAL OFFICER verkauft Aktien von PTC Therapeutics im Wert von 42114 USD (Insiderkauf)
 
Golden, Lee Scott - Vorstand - Tag der Transaktion: 2025-04-02...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!